Current Report Filing (8-k)
December 18 2017 - 10:36AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported) December 15, 2017 (December 14, 2017)
MEDIFIRST
SOLUTIONS, INC
(Exact
name of registrant as specified in its charter)
Nevada
|
|
000-55465
|
|
27-3888260
|
(State
or other
|
|
(Commission
File Number)
|
|
(IRS
Employer
|
jurisdiction
incorporation)
|
|
|
|
Identification
No.)
|
4400 Route 9 South, Suite 1000, Freehold, NJ
|
|
07728
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant's
telephone number, including area code: (732)-786-8044
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01
|
Regulation FD Disclosure
|
On
December 15, 2017, Medifirst Solutions, Inc. (the “Company”) issued a press release announcing that the Company engaged
Life Science Quest, LLC, a consulting group that specializes in globally developing and commercializing the products of health
care and life sciences companies (“Life Quest”).
A
copy of the press release is attached herewith as Exhibit 99.1.
In
addition, attached herewith as Exhibit 99.2 is a copy of a press release dated December 8, 2017, which press release provided
shareholders with an update on various Company initiatives, including the commencement of discussions with Life Quest.
The
information in this Item 7.01 disclosure, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities under that Section. In addition, the information in this Item 7.01 disclosure, including
Exhibits 99.1, shall not be incorporated by reference into the filings of the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, hereunto duly authorized.
|
MEDIFIRST
SOLUTIONS, INC.
|
|
|
Dated:
December 15, 2017
|
By:
|
/s/
Bruce Schoengood
|
|
|
Bruce
Schoengood
President
and Chief Executive Officer
|
2